Recent Findings Beyond weight reduction, GLP-1RAs have shown positive cardiovascular outcomes in patients with elevated ASCVD risk, heart failure with preserved ejection fraction, obstructive sleep apnea, blood pressure, and dyslipidemia
Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice
Unique Features: Semaglutide is the first GLP-1RA shown to reduce cardiovascular events in non-diabetic individuals, making it a notable choice for obesity management
Furthermore, the rising prevalence of obesity has significantly contributed to the growing utilization of GLP-1 analogs in the treatment of obesity, which is significantly driving the GLP-1 analogues market
The best part of getting older, Im finding, is clarity on what I want, comfort in my own body and skin, and a refusal to uphold anything that isnt true to me, regardless of consequence
Healthcare organization must take into account its own hospital and local practices when introducing GLP-1RAs
